Richter’s syndrome - Pipeline Insight, 2021

Richter’s syndrome - Pipeline Insight, 2021

  • June 2021 •
  • 60 pages •
  • Report ID: 6096843 •
  • Format: PDF
“Richter’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Richter’s syndrome Understanding

Richter’s syndrome: Overview
Richter’s Syndrome (RS), also known as Richter’s Transformation, is a rare complication of Chronic Lymphocytic Leukaemia (CLL) and/or Small Lymphocytic Lymphoma (SLL). It is characterised by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma. Richter’s Syndrome occurs in approximately 2-10% of all CLL/SLL patients during the course of their disease.
The most common symptoms of Richter’s Syndrome arise from a sudden and dramatic increase in the size of lymph nodes (also known as ‘lymphadenopathy’) characterised by usually painless areas of swelling in the neck, axilla, abdomen (most commonly in the spleen, also known as ‘splenomegaly’) or groin. Patients also often experience a dramatic increase in unexplained weight loss, fevers and night sweats (often collectively referred to as ‘B-symptoms’).
The definitive or differential diagnosis of Richter’s Syndrome is achieved by an excisional biopsy or CT/ultrasound guided core needle biopsy of an enlarged lymph node that is thought to be indicative of the Richter’s transformation. The current standard first-line treatment for this type of lymphoma is the immuno-chemotherapy using a combination of chemo drugs and a targeted anti-CD 20 monoclonal antibody. Other second-line chemotherapy regimens often used to treat this type of lymphoma (if non-responsive or ‘refractory’ to R-CHOP) include R-ICE, D-HAC, R-DHAP, GIVE, etc.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Richter’s syndrome R&D. The therapies under development are focused on novel approaches for Richter’s syndrome.

Richter’s syndrome Emerging Drugs Chapters
This segment of the Richter’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Richter’s syndrome Emerging Drugs
• Duvelisib: Secura Bio
Duvelisib, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. It is currently in Phase II stage of development for the treatment of Richter’s syndrome and is being developed by Secura Bio.
Further product details are provided in the report……..

Richter’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Richter’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Richter’s syndrome
There are approx. 5+ key companies which are developing the Richter’s syndrome. The companies which have their Richter’s syndrome drug candidates in the most advanced stage, i.e. Phase II include, Secura Bio.
• Phases
This report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Richter’s syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Richter’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Richter’s syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Richter’s syndrome drugs.

Richter’s syndrome Report Insights
• Richter’s syndrome Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Richter’s syndrome Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Richter’s syndrome drugs?
• How many Richter’s syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Richter’s syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Richter’s syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Richter’s syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• TG Therapeutics
• Secura Bio
• AstraZeneca
• Vincerx Pharma
• Merck & Co

Key Products
• Umbralisib
• Duvelisib
• AZD4573
• VIP152
• MK-1026